Why A2M is back in the spotlight

The a2 Milk Company (ASX:A2M; NZX:ATM) has spent the past fortnight fielding two very different kinds of investor scrutiny. The first concerns a batch of share sales by its most senior executives, disclosed to the ASX and NZX in recent change-of-interest notices. The second concerns the company’s full-year results for the 12 months to 30 June 2026, which paired solid headline Revenue growth with a bruising fourth-quarter supply-chain disruption in China — the market that still supplies roughly three-quarters of group sales. Taken together, the two threads have reignited a long-running debate about how much investors should read into the behaviour of a management team steering through a rough patch.

The share sales, in context

According to disclosures lodged with the exchanges, members of a2 Milk’s executive Leadership team sold up to half of the share tranches they received on the recent vesting of FY2024 long-term incentive performance rights. Managing director and chief executive David Bortolussi accounted for the largest single disposal, selling 242,345 shares for about NZ$2.48 million, according to BusinessDesk. Across the nine-strong executive group, the sales exceeded NZ$6 million.

Crucially, the company’s stated rationale is procedural rather than a verdict on the outlook. a2 Milk says the sales were made primarily to meet personal tax obligations that crystallise when performance rights vest, and that its policy permits executives to sell up to the relevant proportion of newly vested shares to cover that tax. The company has also noted that earlier trading windows were constrained by events including the a2 Pokeno acquisition, the divestment of Mataura Valley Milk and the recently paid Special Dividend — so the disposals functioned partly as a catch-up once windows reopened.

Investors weighing the signal should note the counterweights. a2 Milk says every member of the leadership team continues to hold well above the company’s minimum shareholding requirement — set at 100 per cent of fixed remuneration — with Bortolussi retaining roughly 1.52 million shares, described by the company as several times his mandated threshold. At the same time, several non-executive directors have been buying: filings show Grant Dempsey taking an initial 70,000-share stake, alongside on-market purchases by Lain Jager and Sandra Yu. On the disclosure framework itself, Harbour Asset Management’s Oyvinn Rimer has observed that a2 Milk has closed some of the loopholes that were problematic in the past, a tightening Craigs Investment Partners called helpful. In short: the sales are real and sizeable, but the company’s explanation is consistent with tax-driven vesting mechanics rather than a wholesale retreat.

FY2026 results: growth on top, pressure underneath

The financial results help explain why the share register is watching closely. Group revenue rose 12.4 per cent to NZ$1,974.9 million, within touching distance of the NZ$2 billion mark. Underlying EBITDA increased 5.4 per cent to NZ$307.6 million, for a Margin of 15.6 per cent, while reported EBITDA slipped 2.5 per cent to NZ$284.4 million at a 14.4 per cent margin. Gross margin compressed by 3.4 percentage points to 47.7 per cent, reflecting input-cost and mix pressures.

The profit picture was mixed. Underlying net profit after tax rose 7 per cent to NZ$235.8 million, but statutory net profit fell 5.8 per cent to NZ$207.5 million. The gap between the two measures, plus softer second-half earnings, is a large part of why the stock has struggled to hold its recent highs.

The China setback

The quarter that unsettled the market was the fourth. a2 Milk reported that unexpectedly strong third-quarter demand, freight disruption linked to Middle East routing, production backlogs at Manufacturing partner Synlait, extended product-release timeframes and additional customs requirements combined to squeeze availability of its China-label infant formula.

The effect on Market Share was sharp: in the mother-and-baby-store channel, share fell from 4.2 per cent in March 2026 to 2.1 per cent by the fourth quarter, while domestic online share dropped from 4.6 per cent to 1.8 per cent. Full-year China-label infant formula revenue declined 14.0 per cent to NZ$544.3 million.

The English-label, cross-border Business fared far better, with revenue up 27.8 per cent to NZ$714.6 million and market share around 19.5 per cent. Overall infant-formula growth of 4.7 per cent nonetheless marked a sharp deceleration from the prior year’s near-10 per cent pace, even as liquid milk, up 21.8 per cent, and whole-family nutrition, up 59.9 per cent, grew strongly.

By region, China and Asia revenue rose 11.2 per cent to NZ$1,447.6 million, Australia-New Zealand rose 10.2 per cent to NZ$348.2 million, and North America jumped 28.6 per cent to NZ$179 million.

Cash and Capital management

Even after a testing year, the Balance Sheet remains a genuine strength. a2 Milk closed FY2026 with net cash of NZ$784.5 million, down 26.1 per cent from a year earlier after the Pokeno purchase and working-capital investment.

The board lifted the ordinary dividend to 21.0 New Zealand cents per share and paid a special dividend of 41.36 cents — worth about NZ$300 million and settled on 24 July 2026 — both unimputed and fully franked. Management framed the special dividend as a signal of confidence, following regulatory approval of two a2 Pokeno China-label registrations expected to launch in the second half.

Management commentary and outlook

Bortolussi told the results call the company delivered FY2026 results in line with or slightly ahead of its updated April guidance, with double-digit revenue growth, and said a comprehensive recovery plan was in place and execution had commenced. He was candid on the recovery’s pace, describing current China offtake at about 40 per cent of the prior run-rate and cautioning that total sales may not return to pre-crisis levels until the first half of FY2028.

For FY2027, management guided to mid-single-digit revenue growth, with first-half revenue broadly in line with the prior first half, an EBITDA margin of about 15 per cent, and first-half EBITDA materially lower year-on-year as the China recovery builds through the period. Infant-formula sales are expected to be broadly similar to FY2026. Capital Expenditure is guided at roughly NZ$70 million.

The balanced read

For retail investors, a2 Milk in 2026 is a story of a cash-generative Brand navigating a self-described crisis with a credible, if unhurried, recovery plan. The executive share sales look, on the disclosed evidence, like tax-driven housekeeping rather than a loss of faith — a reading reinforced by directors buying and by holdings that remain well above policy minimums.